Align Technology, Inc. research snapshot
ALGN AI stock analysis currently reads Align Technology as a profitable medical device and digital dentistry company with a strong Invisalign brand, high gross margins, and improving 2026 execution after a difficult 2025 reset. At the July 8, 2026 data cutoff, ALGN traded near $185.22 with a verified market capitalization near $13.27 billion. The key debate is whether renewed clear aligner volume growth, international adoption, iTero upgrades, and buybacks can offset dental consumer cyclicality, ASP pressure, competition, and legal or restructuring costs. This page uses scenario ranges, not a certain stock price prediction, and is for informational use only.
Current price
$185.22
Market cap
$13.27 billion
AI score
68 / 100
Rating
Profitable digital dentistry leader, cyclical demand watch
Trend status
Short-term and long-term trend constructive, with price near the 5-day average and above the 20-day, 50-day, and 200-day moving averages
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Align sells Invisalign clear aligners, iTero scanners, and exocad software into orthodontic and restorative dentistry workflows where doctors pay for outcomes, digital efficiency, and patient conversion. | High |
| Moat | The moat comes from brand trust, doctor training, case data, manufacturing scale, software workflow integration, and scanner installed base, but it is exposed to lower-cost aligner competitors and dental platform bundling. | Medium-high |
| Management | CEO Joe Hogan has led Align through international expansion, scanner ecosystem investment, buybacks, and restructuring. Capital allocation now needs proof through durable growth rather than only cost resets. | Medium-high |
| Financial trend | FY2025 revenue was $4.035 billion, up 0.9%, while net income declined 2.6% to $410.4 million. Q1 2026 revenue rose 6.2% year over year to $1.040 billion, led by 7.4% Clear Aligner revenue growth. | High |
| Valuation | At $185.22, ALGN traded near 31.1x trailing EPS, 3.24x sales, 3.20x book value, and 22.7x free cash flow per share based on StockAnalysis metrics and financial_rigor.py verification. | Medium-high |
| Technical trend | Daily technicals were constructive as of July 7, 2026, with ALGN above the 20-day, 50-day, and 200-day simple moving averages and RSI near 58, though price was close enough to the 5-day average to make near-term follow-through important. | Medium |
| Risk level | Risk is medium-high because clear aligners are discretionary medical devices tied to consumer spending, dental office traffic, competition, foreign exchange, tariffs, legal settlements, and product execution. | Medium-high |
| AI confidence | High for reported data and source-backed calculations, medium for forecast and trading setups. | High data confidence |
| Investment certainty | Medium certainty. The page frames watch points and scenario ranges, not a buy or sell instruction. | Medium |
ALGN AI stock forecast
The ALGN AI stock forecast uses scenario math around the $185.22 quote, $5.95 trailing EPS, and the company reaffirming 2026 revenue growth guidance of 3% to 4%. financial_rigor.py produced a three-year bullish value near $223, a base value near $142, and a bearish value near $73 before considering future buybacks, dilution, or multiple changes outside the stated assumptions.
$210 to $225
More likely if Clear Aligner volume stays mid-single digit or better, international regions keep growing, North America remains stable, iTero Lumina upgrades support Systems and Services, non-GAAP margin approaches the 23.7% target, and investors pay a low-to-mid 20s earnings multiple.
$135 to $150
More likely if revenue grows in the low single digits, EPS compounds around high single digits, buybacks help per-share results, but ASP mix, legal costs, and competitive pricing keep the stock near a high-teens earnings multiple.
$70 to $80
More likely if dental consumer demand weakens, clear aligner volume slows, scanner pricing mix worsens, restructuring savings do not protect margins, legal or regulatory costs rise, or the market reprices ALGN closer to a low-teens earnings multiple.
ALGN AI technical analysis
ALGN AI technical analysis is constructive but not risk-free as of the July 8, 2026 data cutoff. Investing.com showed daily technicals as strong buy on July 7, 2026, with RSI(14) at 58.121, the stock above the 20-day, 50-day, and 200-day simple moving averages, and classic pivot levels clustered around $184.96 support and $185.81 resistance.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $185.22 | Used for financial_rigor.py market cap and valuation checks at the July 8, 2026 data cutoff. |
| Near support | $184.96 to $185.00 | Investing.com listed classic S1 near $184.96 and Fibonacci S1 near $184.97 on July 7, 2026. |
| Deeper support | $174 to $178.60 | The 200-day simple moving average was $174.09 and the 50-day simple moving average was $178.58, making this the trend support band to monitor. |
| Near resistance | $185.80 to $186.15 | Classic R1 and R2 pivot levels were near $185.81 and $186.14, with Woodie R3 near $186.74. |
| Intermediate resistance | $200 to $210 | This zone is not a guaranteed target. It marks where the stock would need improving volume, margin confirmation, and earnings estimate support to extend the recovery. |
| Moving averages | MA20 $184.94, MA50 $178.58, MA200 $174.09 | Investing.com listed these daily simple moving averages on July 7, 2026; holding above MA50 and MA200 keeps the recovery trend intact. |
| Momentum | RSI(14) 58.121 | RSI was positive but not extremely overbought, so confirmation depends more on earnings, guidance, and volume than on RSI alone. |
| Volume | Watch volume versus the 20-day and 50-day averages | A breakout above the $186 area has higher quality if volume expands rather than fading near the pivot band. |
| Volatility | ATR(14) 2.2428 | Investing.com listed ATR(14) near $2.24, supporting wider stops than a tight one-day pivot would imply. |
| Invalidation | Close below $174 | A decisive close below the 200-day simple moving average would weaken the long-term trend framework and lower confidence in trend-following setups. |
ALGN AI trading strategy
The ALGN AI trading strategy is a rules-based research framework for a medical device stock tied to dental demand, international adoption, and margin recovery. It is not personal advice and should be paired with fresh chart data, filings, position sizing, and a defined invalidation level.
Watch for ALGN to hold above the 20-day and 50-day moving averages, clear the $186 pivot band on expanding volume, and confirm with Q2 2026 revenue, clear aligner volume, ASP, and margin commentary.
A close back below the 50-day average lowers near-term trend confidence. A close below the 200-day average should invalidate the recovery setup.
If ALGN pulls back toward the $174 to $179 moving average band without a negative guidance reset, compare the pullback with dental demand commentary, scanner mix, legal costs, and buyback activity before assuming support is durable.
Do not average down without a maximum loss rule because ALGN can gap on earnings, consumer demand, litigation, or competitive pricing news.
Track Clear Aligner case volume, North America stability, EMEA and APAC growth, GP dentist adoption, iTero Lumina unit mix, non-GAAP operating margin, cash generation, repurchases, and any change to 2026 guidance.
Reduce confidence if revenue growth depends mainly on buybacks or foreign exchange while patient traffic, ASP, and gross margin weaken.
Investment research summary
Align sells digital orthodontic and restorative dentistry outcomes. Doctors and dental organizations pay because Invisalign, iTero, exocad, and related software can improve treatment planning, patient conversion, office workflow, and brand confidence.
The moat is built on Invisalign brand awareness, doctor training, clinical case history, proprietary treatment planning software, manufacturing scale, scanner workflows, and a large installed ecosystem. It narrows if lower-cost aligners, in-office printing, or bundled dental platforms reduce switching costs.
The thesis fails if dental demand weakens, North America loses stability, competitors compress ASP, scanner upgrades slow, legal costs persist, or management uses buybacks to hide weak organic growth.
Joe Hogan and the leadership team have expanded Align internationally, invested in digital dentistry, and used buybacks. The key scorecard is whether restructuring and reinvestment produce durable volume growth, margin recovery, and product adoption rather than a short earnings rebound.
Digital dentistry is a long-duration trend because orthodontics and restorative workflows are moving toward scanning, software planning, and integrated doctor-patient platforms. The trend is real, but adoption is still tied to consumer budgets, practice economics, and regulatory or clinical trust.
At roughly 31.1x trailing EPS and 22.7x free cash flow per share, ALGN needs sustained growth and margin recovery to justify the current price. Margin of safety improves if price returns to the moving average support band while volume growth, cash conversion, and guidance remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ALGN price and market capitalization | $185.22 price, $13.27 billion verified market cap | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 71.62 million shares outstanding | StockAnalysis statistics | July 8, 2026 |
| FY2025 revenue | $4.035 billion, up 0.9% year over year | Align FY2025 financial results | July 8, 2026 |
| FY2025 net income | $410.4 million, down 2.6% year over year | Align FY2025 financial results | July 8, 2026 |
| Q1 2026 revenue | $1.040 billion, up 6.2% year over year; Clear Aligner revenue up 7.4% | Align Q1 2026 financial results | July 8, 2026 |
| Cash and equivalents | $1.0598 billion at March 31, 2026 | Align Q1 2026 financial results | July 8, 2026 |
| Valuation ratios | 31.12x trailing PE, 16.20x forward PE, 3.24x sales, 22.73x free cash flow | StockAnalysis statistics | July 8, 2026 |
| Technical snapshot | RSI(14) 58.121; MA20 $184.94, MA50 $178.58, MA200 $174.09 | Investing.com technical analysis | July 8, 2026 |
This ALGN AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast ranges are scenario outputs based on available public data and can be wrong if fundamentals, valuation multiples, technical conditions, or market sentiment change.
